Savara (NASDAQ:SVRA) Shares Gap Up After Analyst Upgrade

Savara Inc (NASDAQ:SVRA)’s share price gapped up before the market opened on Wednesday after Guggenheim raised their price target on the stock from $8.00 to $10.00. The stock had previously closed at $3.80, but opened at $4.42. Guggenheim currently has a buy rating on the stock. Savara shares last traded at $3.89, with a volume of 12,854,905 shares trading hands.

SVRA has been the subject of a number of other research reports. Evercore ISI decreased their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 16th. Oppenheimer boosted their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday. HC Wainwright boosted their price target on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. JMP Securities restated a “market outperform” rating and set a $8.00 price target on shares of Savara in a research note on Monday, May 6th. Finally, Piper Sandler boosted their price target on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Savara has a consensus rating of “Buy” and a consensus price target of $11.00.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Savara by 2.3% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock worth $72,536,000 after buying an additional 332,706 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Savara by 0.3% in the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after buying an additional 26,613 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock worth $30,008,000 after buying an additional 1,874,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Savara by 41.1% during the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after purchasing an additional 746,407 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Performance

The firm has a market capitalization of $526.50 million, a PE ratio of -10.30 and a beta of 0.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. The company’s fifty day simple moving average is $4.32 and its 200 day simple moving average is $4.63.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts expect that Savara Inc will post -0.41 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.